DM Intelligence

Established in 2018 and based in Guangzhou, China, DM Intelligence Ltd. is a company focuses on pharmaceutical technology and medical imaging diagnosis through artificial intelligence researches, innovations and applications. DM Intelligence Ltd. focuses on building an AI-powered new drug creation. Using AI, DM Intelligence Ltd. established a comprehensive algorithm model from the dimensions of medicinal chemistry, biology, mathematics and bioinformatics to obtain novel and diverse active compounds. The introduction of AI technology in the drug development process, the use of deep learning technology to analyze and process molecular structures, and the establishment of a predictive system with higher accuracy in different research and development links can reduce the uncertainty of each research and development link and to achieve the development cycle, reducing the cost of trial and error. The AI new drug creation platform is based on massive databases, combined with CADD and machine learning and deep learning algorithms to meet the needs of drug activity and ADMET property prediction, drug-target interaction, and small molecule generation. It uses supercomputing to accelerate new drug hits, lead discovery, PCC optimization. Using this platform, the team can obtain experimentally verified, novel and diverse structures that break through patent barriers in a relatively short period of time. At present, the company has developed more than 10 internal pipelines and 5 external cooperation pipelines, focusing on small molecule targeted drug pipelines that have been verified and urgently need to be marketed in the fields of tumor, neurodegeneration, infection and autoimmunity. Next, the company will focus on the construction of AI new drug creation platform, and accelerate the development of Parkinson and other key pipelines.

1. Angel

   Apr 21, 2021

   Amount

   Undisclosed

   Investors

   Locked